Additionally, mutations that were previously reported in GBM were detected at a lower frequency compared to TERT alterations across our cohort, including mutations in NF1 (n = 3 patients, 25% cases), EGFR (n = 5, 41.7% cases), TP53 (n = 4, 33.3%), RB1 (n = 1, 8.3%), TSC1 (n = 1, 8.3%). This evidence concerns the gene TP53 and glioblastoma.